Novavax, Inc. has 1,172 employees, according to Revelio Labs workforce intelligence data. The YoY growth rate is -33.6%.
Data source: Revelio Labs Coverage: Global workforce Latest update: September 2025
Novavax AB is a fully owned subsidiary of Novavax Inc. a late-stage biotechnology company focused on the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Product Pipeline Our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("RSV"), seasonal influenza, pandemic influenza, and Ebola virus ("EBOV"). We have additional preclinical-stage programs for a variety of infectious diseases. Corporate Overview Novavax is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
As of September 2025
Novavax
workforce metrics
Headcount
1.2k
Avg. Salary
$144.6k
Tenure
3.8yr
Growth Rate
-33.6%
Hiring Rate
Attrition Rate
For even more metrics data,
reach out to our sales team.
Interactive chart of Novavax annual worldwide employee count from 2023 to 2025.
Would you like to see the latest employee headcount data?
Would you like to see the latest employee geographic data?
Interactive chart of Novavax annual active job postings from 2023 to 2025.
Would you like to see the latest active job postings data?
Sentiment Topics
Would you like to see the latest employee sentiment data?